Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal 13-valent conjugate vaccine (Pfizer, bcdb7c)
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Pneumococcal 13-valent conjugate vaccine** is Pfizer's CRM197-conjugated, aluminum-phosphate-adsorbed pneumococcal vaccine marketed as **Prevnar 13** and **Prevenar 13**. It contains capsular polysaccharides from 13 *Streptococcus pneumoniae* serotypes, individually conjugated to the nontoxic diphtheria-derived carrier protein CRM197. Vaccination induces serotype-specific antibody responses, including opsonophagocytic activity, to prevent pneumococcal disease caused by vaccine serotypes, including invasive pneumococcal disease and pneumococcal pneumonia. Pfizer identifies this specific 13vPnC product by compound number PF-05208760. ([cdn.pfizer.com](https://cdn.pfizer.com/pfizercom/clinical%20trials/csr%20synopsis/B1851172%2520PDS.pdf))
- Brand names
- Prevnar 13Prevnar13Prevnar-13Prevenar 13Prevenar13Prevenar-13
- Other names
- 13vPnCPCV13PCV-13PCV 13pneumococcal polysaccharide conjugate vaccine 13-valent adsorbed
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on pneumococcal 13-valent conjugate vaccine (Pfizer, bcdb7c).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal 13-valent conjugate vaccine (Pfizer, bcdb7c).